Full-Time

Senior Director

Market Access Strategy, Heme

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$235.2k - $352.8k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

This position requires the candidate to be local and able to be in the office on a weekly basis, specifically three days a week.

Category
Strategy Development
Business Development
Business & Strategy
Requirements
  • Expert knowledge of US healthcare system, including gov’t & commercial payers, policy, and regulatory environment
  • Strong understanding of the hospital setting, billing and coding requirement as well as the flow of funds coupled with cell & gene experience
  • Previous contract strategy leadership experience in the pharmaceutical/biotech or healthcare industry (required)
  • Experience in developing and articulating a clear and pragmatic value proposition
  • Proven track record of meeting or exceeding objectives & goals, both as an individual and as part of a team
  • Excellent communication skills with experience presenting to customers and internal leadership
  • Demonstrated ability to successfully lead cross-functional teams, influencing without direct authority, with the interpersonal skills to foster collaboration and succeed in a highly matrixed environment
  • Ability to perform in a fast-paced environment, manage multiple priorities simultaneously, and work effectively across cross-functional teams
  • Must have US Access launch experience
  • Experience with leading and managing a team
Responsibilities
  • Provide critical leadership in developing brand and market access strategies by payer channel, to support patient access for Casgevy in the creation and delivery of impactful market access resources
  • Coach/player mindset to lead a team to ensure all strategies and tactics are well thought through and aligned to overarching brand strategy
  • Plays a critical leadership role within the Heme Business Unit leadership team representing all market access functions
  • Lead CMMI CGT Access Model execution; pull-through at the field level and education of ATCs in applicable states
  • Execution and refinement of the Casgevy market access strategy
  • In tandem with BULT, ARLs, payer and trade field team to drive demand
  • Spearhead and create an alternative contracting strategy in tandem with the MA cross functional team and GVAS
  • Develop, train, and implement the necessary promotional resources and reimbursement pull-through that support field account teams’ efforts with key customers
  • Oversee and provide strategic input and planning for future formulations, conditioning regiments, etc.
  • Chair the Heme ACCESS process across the cross-functional business partners
  • Customize strategies based on Commercial, Medicaid & Medicare demographics, legislation, & trends
  • Identify and address key product barriers to payer access and performance by applying advanced payer analytics and market trends
  • Oversee agency and external vendors to deliver resources and strategic insights on time and within budget
  • Developing KPIs and metrics to assess impact of key initiatives
  • Act as trusted, subject matter expert on US payer landscape to internal colleagues and externally customers
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased focus on personalized medicine aligns with Vertex's patient-centric approach.

What critics are saying

  • Increased competition in cystic fibrosis could impact Vertex's market share.
  • Regulatory changes in the EU may delay Vertex's drug approvals.
  • High R&D costs and potential trial failures could strain Vertex's finances.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.